TNFSF4 and asthma: Additionally, in a recent phase IIb randomized control trial (RCT) of patients with moderate-to-severe asthma, amlitelimab, a fully human monoclonal antibody that binds to OX40 receptor and its cognate ligand OX40L, impedes T2 polarization of naive T cells (Lé and Torres, 2022; ClinicalTrials.gov, 2023).